[Stress Mediated Microglial Hyper-Activation and Psychiatric Diseases]

Area of Science:

• Neuroscience
• Psychiatry
• Immunology

Background:

• Stress is a known trigger for depression and post-traumatic stress disorder (PTSD).
• Microglial hyperactivation and dysfunction are increasingly recognized in the pathophysiology of these stress-related psychiatric disorders.
• Microglia play crucial roles in brain immunity, synaptic plasticity, and neuronal function.

Purpose of the Study:

• To review microglial functional changes in animal models and human studies related to depression and PTSD.
• To explore the role of microglial cytokine and neurotrophic factor release in stress-induced behavioral changes.
• To investigate the potential of reverse-translational research using human peripheral blood to understand microglial involvement in depression.

Main Methods:

• Review of animal models exhibiting PTSD-like fear memory dysregulation.
• Analysis of human clinical studies focusing on microglia in depression and PTSD.
• Examination of positron emission tomography (PET) studies using TSPO ligands in patients.
• Conducting reverse-translational research using human peripheral blood samples.

Main Results:

• Animal models show abnormal microglial cytokine production linked to fear memory deficits and generalization in PTSD.
• Impaired microglial phagocytosis may contribute to fear generalization and forgetting.
• PET studies suggest enhanced microglial inflammation in depression but suppressed inflammation in PTSD.
• Human peripheral blood analysis is being used to explore microglial roles in depression.

Conclusions:

• Microglial dysfunction is central to the pathophysiology of stress-related disorders like depression and PTSD.
• Abnormalities in microglial cytokine release and phagocytosis significantly impact fear memory processing.
• Discrepant inflammatory profiles in microglia between depression and PTSD warrant further investigation.
• Integrated human and animal research is essential for understanding these disorders and developing targeted therapies.